18th Apr 2019 10:48
LONDON (Alliance News) - Silence Therapeutics PLC said on Thursday Interim Chief Financial Officer Rob Quinn has been promoted to the role on a permanent basis with immediate effect.
He will be replacing David Ellam, who left in January after three years in the role.
Quinn has been in the interim role since then, and before that was head of financial planning & analysis at the genetic medicines firm for a year from 2017.
Prior to that, Quinn was a part of FTSE 100-listed GlaxoSmithKline PLC for four years from 2013, leaving as an area finance director for Africa & Developing Countries.
"I'm very pleased that Rob will serve as full time chief financial officer and on behalf of the board I would like to formally welcome him to this role. Rob's scientific and financial skills, alongside his commercial acumen make him an asset to the Silence team. During his time at the company he has continued to play an important role in building the business, with a keen appreciation for how we will grow in the future," said Chief Executive David Solomon.
Shares in Silence Therapeutics were untraded on Thursday, last quoted at 58.40 pence.
Related Shares:
SLN.LGlaxosmithkline